Modulation of matrix remodeling by SPARC in neoplastic progression

被引：121

作者：

Chlenski, Alexandre ^{[1
]}

Cohn, Susan L. ^{[1
]}

机构：

[1] Univ Chicago, Dept Pediat, Hematol Oncol Sect, Chicago, IL 60637 USA

来源：

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY | 2010年 / 21卷 / 01期

关键词：

SPARC; Cancer; Tumor microenvironment; Matrix remodeling; FIBROBLAST-GROWTH-FACTOR; ENDOTHELIAL-CELL PROLIFERATION; MATRICELLULAR PROTEIN SPARC; CALCIUM-BINDING DOMAINS; INTEGRIN-LINKED KINASE; BREAST-CANCER CELLS; SECRETED PROTEIN; EXTRACELLULAR-MATRIX; CYSTEINE SPARC; NULL MICE;

D O I：

10.1016/j.semcdb.2009.11.018

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

SPARC is a matricellular glycoprotein that mediates interactions between cells and their microenvironment. It is produced at sites of tissue remodeling, where it regulates matrix deposition and turnover, cell adhesion, and signaling by extracellular factors, exerting profound effects on tissue architecture and cell physiology. During extensive matrix remodeling in neoplastic progression, SPARC is expressed in cancer-associated stroma and in malignant cells of some types, affecting tumor development, invasion, metastases, angiogenesis and inflammation. SPARC-induced changes in the tumor microenvironment can suppress or promote progression of different cancers depending on the tissue and cell type. Understanding the mechanism of matrix remodeling and its regulation by SPARC is essential for the development of new treatment strategies for highly aggressive cancers. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：55 / 65

页数：11

共 146 条

[11] Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells [J].

Briggs, J ;

Chamboredon, S ;

Castellazzi, M ;

Kerry, JA ;

Bos, TJ .

ONCOGENE, 2002, 21 (46) :7077-7091

[12] Genetic and Epigenetic Alterations of Familial Pancreatic Cancers [J].

Brune, Kieran ;

Hong, Seung-Mo ;

Li, Ang ;

Yachida, Shinichi ;

Abe, Tadayoshi ;

Griffith, Margaret ;

Yang, Dawei ;

Omura, Noriyuki ;

Eshleman, James ;

Canto, Marcia ;

Schulick, Rich ;

Klein, Alison P. ;

Hruban, Ralph H. ;

Iacobuzio-Donohue, Christine ;

Goggins, Michael .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (12) :3536-3542

[13] Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein [J].

Chandrasekaran, Vasu ;

Ambati, Jayakrishna ;

Ambati, Balamurali K. ;

Taylor, Ethan Will .

JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 26 (04) :775-782

[14] SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response [J].

Cheetham, S. ;

Tang, M. J. ;

Mesak, F. ;

Kennecke, H. ;

Owen, D. ;

Tai, I. T. .

BRITISH JOURNAL OF CANCER, 2008, 98 (11) :1810-1819

[15] SPARC enhances tumor stroma formation and prevents fibroblast activation [J].

Chlenski, A. ;

Guerrero, L. J. ;

Yang, Q. ;

Tian, Y. ;

Peddinti, R. ;

Salwen, H. R. ;

Cohn, S. L. .

ONCOGENE, 2007, 26 (31) :4513-4522

[16] SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix [J].

Chlenski, A ;

Liu, SQ ;

Guerrero, LJ ;

Yang, QW ;

Tian, YF ;

Salwen, HR ;

Zage, P ;

Cohn, SL .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) :310-316

[17] Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC [J].

Chlenski, A ;

Liu, SQ ;

Baker, LJ ;

Yang, QW ;

Tian, YF ;

Salwen, HR ;

Cohn, SL .

CANCER RESEARCH, 2004, 64 (20) :7420-7425

[18]

Chlenski A, 2002, CANCER RES, V62, P7357

[19] COMPLEX-FORMATION OF HUMAN THROMBOSPONDIN WITH OSTEONECTIN [J].

CLEZARDIN, P ;

MALAVAL, L ;

EHRENSPERGER, AS ;

DELMAS, PD ;

DECHAVANNE, M ;

MCGREGOR, JL .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (02) :275-284

[20]

CLEZARDIN P, 1991, J BONE MINER RES, V6, P1059

← 1 2 3 4 5 6 7 8 9 10 →